Nanobody Therapeutic Pipeline — PatSnap Eureka
Antibody Fragment & Nanobody Therapeutic Pipeline
Single-domain VHH antibodies (~15 kDa) are redefining biotherapeutics — from biparatopic CD38 constructs achieving CDC in multiple myeloma, to BBB-penetrant vectors for tau and alpha-synuclein. Explore the full patent and literature landscape with PatSnap Eureka.
Seven VHH Modality Classes Shaping the Nanobody Pipeline
From monovalent scaffolds to AAV-delivered gene therapy, the nanobody field has evolved far beyond first-generation single-domain discovery. Each modality addresses distinct unmet needs across oncology, immunology, infectious disease, and neurology.
Monovalent VHH / Single-Domain Antibodies
The foundational modality: monomeric VHH (~15 kDa) recombinantly produced from camelid heavy-chain-only antibody variable domains. Structural advantages include single-gene encoding, absence of light chain, long CDR3 loops capable of penetrating enzyme active sites and receptor crevices, high thermostability, and expression in prokaryotic and yeast systems. Academic literature from life sciences institutions provides the structural foundation for all subsequent modalities.
Preclinical → ClinicalBivalent and Multivalent VHH Constructs
Two architectures: homobivalent (two copies joined by linkers) exploiting avidity for picomolar potency, and heterobivalent or biparatopic (two VHHs against distinct, non-overlapping epitopes). The bivalent TNF-α VHH study demonstrates picomolar antagonism from intramolecular interactions unavailable to monomers. The CD38 biparatopic hcAb system shows epitope complementarity is essential for effective complement-dependent cytotoxicity. Ablynx/Sanofi vWF nanobody advanced to approval for acquired thrombotic thrombocytopenic purpura.
Preclinical → Early ClinicalCNS-Penetrant VHH & BBB-Crossing Strategies
Addresses the failure of conventional IgG to cross the blood–brain barrier. Strategies include transcytosis via transferrin receptor-binding VHHs, direct intranasal administration, and engineered receptor-mediated transport. A CNRS patent explicitly claims use of VHH antibodies as peptide vectors for transporting substances across the BBB via receptor-mediated mechanisms. Targets include alpha-synuclein, tau, and amyloid-beta. Only one active patent in this dataset specifically claims VHH as a BBB-crossing vector — a significant white space.
Predominantly PreclinicalIntracellular Nanobodies (Intrabodies)
Deploys nanobodies against intracellular targets, circumventing the disulfide-bond dependence of conventional IgG in the reducing cytoplasmic environment. Harvard Medical School / HHMI examined 75 nanobodies from the Protein Data Bank, finding the majority unstable intracellularly, and developed a framework mutagenesis strategy to stabilize them without compromising antigen binding. A TRIMbody approach fusing VHH to the RBCC motif of TRIM21 enables targeted intracellular protein degradation.
Preclinical / Proof-of-ConceptNanobody-Based CAR-T & Immune Cell Engineering
Nanobody antigen-binding domains substitute for conventional scFv in CAR-T constructs, with applications across more than ten tumor-specific targets including BCMA. Anti-BCMA nanobody CAR-T demonstrates comparable clinical effects to scFv-modulated CAR-T. VHH-based constructs also appear in NK cell engagement strategies (Affimed multispecific CD16A-engaging formats) and CD28 single-domain antibody patent filings (Inhibrx). Explore the patent landscape for CAR-T VHH innovations.
Preclinical → Early ClinicalAAV-Delivered Nanobody Gene Therapy
AAV vectors enable sustained in vivo nanobody expression, applicable to CNS, cardiovascular, metabolic, and oncological indications. RegenxBio holds multiple active patent filings for rAAV-delivered antibody fragments including anti-Aβ, anti-tau, and anti-sortilin mAb equivalents. Academic literature provides a systematic review of AAV-nanobody combinations in preclinical disease models. AAV9 and related serotypes with CNS tropism combined with VHH transgenes are explicitly described as a combined modality. Programs must develop IP covering not only the VHH sequence but also vector serotype, promoter, and tissue targeting.
Preclinical → IND-enablingFrom Cytokine Axes to Viral Envelopes: VHH Target Landscape
The nanobody therapeutic dataset spans a broad target landscape. Cytokine signaling axes — IL-23 (p19 and p40 subunits), IL-17A, TNF-α, and TGF-β — are recurring targets for VHH-mediated neutralization in inflammatory and autoimmune conditions. Crystal structure of a quaternary complex of hIL-23 with nanobodies against both p19 and p40 subunits enabled rational design of a multivalent, highly specific blocking nanobody exploiting distinct, non-overlapping epitopes. PatSnap's life sciences intelligence platform tracks all active Janssen Biotech patent filings covering human anti-IL-23p19 antibodies.
Immune checkpoint molecules PD-1, PD-L1, and CD38 emerge as prominent targets. Innovent Biologics holds an active EP patent for humanized anti-PD-L1 nanobodies blocking PD-1/PD-L1 binding with high affinity and specificity. CD38 biparatopic hcAb combinations against three non-overlapping CD38 epitopes mediate potent CDC against multiple myeloma cell lines, whereas monospecific hcAb monotherapy does not — strongly supporting the mechanistic rationale for biparatopic design in hematological malignancies.
Viral targets include SARS-CoV-2 spike RBD and HIV envelope glycoproteins (gp120/gp41). Multiple studies identify VHHs accessing the ACE2-binding cleft with picomolar to femtomolar affinity. Multivalent Nb constructs achieved half-maximal inhibitory concentrations as low as 0.058 ng/ml. Long CDR3 VHH loops access canyon epitopes on the HIV envelope inaccessible to conventional WHO-tracked IgG therapies. CNS targets alpha-synuclein, tau, and amyloid-beta are candidates for sdAb-based strategies exploiting BBB-crossing VHH vectors.
Purinergic signaling targets — CD38, CD39, CD73, P2X7, and Adora2a — are highlighted as addressable by nanobody-based biologics in inflammation and tumor immunosuppression, as documented by University Medical Center Hamburg-Eppendorf research.
Patent & Literature Data: Nanobody Field at a Glance
Key quantitative signals from patent and academic literature analysis via PatSnap Eureka, covering potency benchmarks, target distribution, and modality readiness.
VHH Neutralization Potency by Target
Relative potency ranking of nanobody/VHH constructs across key targets, based on affinity class reported in patent and literature records.
Innovation Activity: Commercial vs. Academic
Patent and literature signals in the dataset are distributed between commercial IP-driven entities and academic/literature-driven research institutions.
VHH Target Coverage by Therapeutic Area
Target density across four major therapeutic areas in the retrieved dataset — oncology, immunology/autoimmune, infectious disease, and CNS/neurological.
Emerging Combination & Format Strategies
Convergent modality combinations identified in the patent and literature dataset, representing next-generation nanobody therapeutic architectures.
IP Strategy & Competitive Intelligence Signals
Key strategic implications derived from patent and literature signals in the PatSnap Eureka dataset — for IP strategists, R&D leads, and business development teams.
Biparatopic Design Is a Potent Differentiation Strategy
Data from both the CD38 hcAb and IL-23 nanobody studies demonstrate that epitope complementarity — engaging two distinct, non-overlapping binding sites on the same antigen — unlocks mechanisms (CDC, cytokine blockade, avidity) unavailable to monospecific constructs. IP strategists should evaluate biparatopic VHH combinations as patentable innovations distinct from individual VHH sequences.
BBB Penetration via VHH Is a Largely Unmet IP Space
Only one active patent (CNRS, EP) in this dataset specifically claims VHH as a BBB-crossing vector. Given the strong academic evidence base and high CNS disease burden, this represents a significant opportunity for new patent filings combining CNS-penetrant VHH scaffolds with specific neurological disease targets (tau, alpha-synuclein, amyloid-beta).
Key Commercial & Academic Innovators in the Dataset
Patent and literature activity is distributed across commercial IP-driven entities and academic research institutions, with patent activity skewing toward second-generation formatted constructs.
| Assignee / Institution | Country | Key Focus | IP Status |
|---|---|---|---|
| Ablynx N.V. (acquired by Sanofi) | Belgium | Improved VHH constructs against vWF; aggregation-mediated thrombotic disorders | Active EP Patents |
| Innovent Biologics (Suzhou) | China | Humanized anti-PD-L1 nanobody; PD-1/PD-L1 checkpoint blockade | Active EP Patent |
| Inhibrx, Inc. | USA | CD28 single-domain antibodies; multivalent/multispecific constructs for cancer | Patent Pending (IL) |
| RegenxBio Inc. | USA | rAAV-delivered antibody fragments; anti-Aβ, anti-tau, anti-sortilin for CNS | Multiple SG Patents |
| CNRS (France) | France | VHH-based BBB peptide vectors for substance delivery; IL-23, TNF-α structural studies | Active EP Patent |
| Children's Medical Center Corp. (Harvard-affiliated) | USA | VHH conjugates for autoimmune disease treatment | Active/Pending IL Patents |
| Zhejiang Daor Biotechnology | China | Anti-CLDN18A2 nanobody for gastric/pancreatic cancer | Active JP Patent |
| Univ. Medical Center Hamburg-Eppendorf | Germany | Biparatopic CD38 hcAbs; cDNA immunization; purinergic signaling nanobody biologics | Academic (3 papers) |
| Howard Hughes Medical Institute / Harvard | USA | Systematic intracellular nanobody stabilization (75 VHHs examined) | Academic (2 papers) |
| VIB-UGent Center for Medical Biotechnology | Belgium | Intracellular sdAb reviews; viral infection VHH formats | Academic (2 papers) |
Track Every Nanobody Patent Filing in Real Time
PatSnap Eureka monitors patent activity across all assignees, jurisdictions, and VHH format classes — updated continuously from PatSnap's analytics platform.
Translational Readiness: From Preclinical to IND-Adjacent
Retrieved results contain limited but notable clinical translation signals. Netakimab (BCD-085) is described in crystal structure papers as an anti-IL-17A antibody containing a VHH domain in clinical development, with the hybrid Fab format characterized as a drug candidate. The conventional VH domain is replaced by a llama VHH with a long CDR-H3, demonstrating high-affinity IL-17A binding.
The RegenxBio rAAV platform patent filings explicitly reference clinical-stage anti-Aβ antibodies (solanezumab, lecanemab), anti-tau mAbs (ABBV-8E12, UCB-0107, NI-105/BIIB076), and anti-sortilin (AL-001) as benchmark molecules for fully human AAV-delivered antibody therapeutics — signaling IND-enabling or clinical-adjacent positioning. NIH and academic groups are tracking AAV-nanobody convergence as a priority CNS delivery modality.
Nanosota-1C-Fc is characterized as a drug candidate development program with preclinical efficacy data in hamster and mouse models at a single dose. Multivalent Nb constructs achieved IC50 as low as 0.058 ng/ml, with Fc-tagged format providing pharmacokinetic extension.
Anti-BCMA nanobody CAR-T retrieved literature states that constructs using single or bivalent nanobody display "comparable clinical effects" to scFv-modulated CAR-T, suggesting clinical experience is being referenced. No retrieved result explicitly describes FDA or EMA approval status, reported trial outcomes, or regulatory submissions with verifiable dates for nanobody-specific programs. Clinical signals are therefore characterized as translational or IND-adjacent. Explore how PatSnap customers track clinical-stage biologics programs.
Nanobody & VHH Therapeutics — Key Questions Answered
Single-domain antibodies (sdAbs), particularly camelid-derived VHH domains (nanobodies), are distinguished by their small size (~15 kDa), high stability, and unique capacity to access cryptic epitopes inaccessible to conventional IgG formats. They feature single-gene encoding, absence of light chain, long CDR3 loops capable of penetrating enzyme active sites and receptor crevices, high thermostability, and expression in prokaryotic and yeast systems.
Biparatopic VHH constructs engage two distinct, non-overlapping epitopes on the same target antigen. The CD38 biparatopic heavy-chain antibody system shows that epitope complementarity is essential for effective complement-dependent cytotoxicity (CDC), whereas monospecific hcAb monotherapy does not achieve this. This design principle unlocks mechanisms unavailable to monospecific constructs and is applicable across multiple tumor-associated antigens.
Retrieved literature from Sanofi systematically reviews VHH and VNAR approaches to brain delivery including transcytosis via transferrin receptor-binding VHHs, direct intranasal administration, and engineered receptor-mediated transport. A CNRS patent explicitly claims use of VHH antibodies as peptide vectors for transporting substances of interest across the BBB via receptor-mediated mechanisms.
Harvard Medical School studies examined 75 nanobodies from the Protein Data Bank, finding the majority unstable intracellularly, and developed a framework mutagenesis strategy to stabilize them without compromising antigen binding. The reducing cytoplasmic environment poses challenges for conventional IgG fragments, making intracellular stability a critical unresolved bottleneck for intrabody programs.
Retrieved clinical translation signals include: Netakimab (BCD-085), an anti-IL-17A antibody containing a VHH domain characterized as a drug candidate; the Nanosota-1C-Fc program with preclinical efficacy data in hamster and mouse models; anti-BCMA nanobody CAR-T reported to demonstrate comparable clinical effects to scFv-based CAR-T; and the Ablynx vWF nanobody program referenced in patent filings covering prophylactic and therapeutic purposes. No retrieved result explicitly describes FDA or EMA approval status for nanobody-specific programs.
The molecular targets most prominently addressed include cytokine signaling axes (IL-23, IL-17A, TNF-α, TGF-β), immune checkpoint molecules (PD-1, PD-L1, CD38), von Willebrand Factor (vWF) for thrombotic conditions, viral targets (SARS-CoV-2 spike RBD, HIV gp120/gp41), and CNS targets including alpha-synuclein, tau, and amyloid-beta for neurological conditions.
Still have questions? Let PatSnap Eureka search the nanobody patent and literature database for you.
Ask PatSnap Eureka About NanobodiesAccelerate Your Nanobody & VHH Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, identify white spaces, and track emerging biparatopic, CNS-penetrant, and AAV-delivered nanobody programs.
References
- Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex — AFMB, Aix-Marseille Université, 2017
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunity — The Jackson Laboratory, 2009
- A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation — University Medical Center Hamburg-Eppendorf, 2018
- Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions — CNRS, Marseille, 2017
- The Therapeutic Potential of Nanobodies — University of Ljubljana, 2019
- The Application of Nanobody in CAR-T Therapy — Xinxiang Medical University, 2021
- CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells — University Medical Center Hamburg-Eppendorf, 2018
- Anti-PD-L1 Nanobody and Use Thereof — Innovent Biologics (Suzhou) Co., Ltd., 2021, EP [Patent]
- Improved Nanobodies™ for the Treatment of Aggregation-Mediated Disorders — Ablynx N.V., 2020, EP [Patent]
- The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization — Tehran University of Medical Sciences, 2021
- Nanobodies that Neutralize HIV — QVQ Holding bv, Utrecht, 2019
- Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR — Sanofi, 2020
- Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases — National Research Council Canada, 2019
- Use of VHH Antibodies for the Preparation of Peptide Vectors for Delivering a Substance of Interest — CNRS, 2018, EP [Patent]
- A general approach for stabilizing nanobodies for intracellular expression — Howard Hughes Medical Institute / Harvard Medical School, 2021
- An Inside Job: Applications of Intracellular Single Domain Antibodies — VIB-UGent, 2020
- A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment — Fudan University, 2021
- CD28 Single Domain Antibodies and Multivalent and Multispecific Constructs Thereof — Inhibrx, Inc., 2022 [Patent]
- NK Cell Engaging Antibody Fusion Constructs — Affimed GmbH, 2020 [Patent]
- A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies — Universidad ORT Uruguay, 2021
- Fully-Human Post-Translationally Modified Antibody Therapeutics — RegenxBio Inc., 2021 [Patent]
- Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality — Elasmogen Ltd., 2017
- World Health Organization (WHO) — Global biotherapeutics regulatory reference
- National Institutes of Health (NIH) — CNS drug delivery and neurological disease research
- European Medicines Agency (EMA) — Biologic regulatory framework reference
- Centre National de la Recherche Scientifique (CNRS) — VHH BBB-crossing vector patent holder
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a targeted patent and literature dataset and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.